Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model

Journal of Alzheimer's Disease

Volumn 39, Issue 2, 2014, Pages 357-370

  Ribeiro, Carlos A ^a,b   Oliveira, Sandra Marisa ^a   Guido, Luis F ^b   Magalhães, Ana ^a   Valencia, Gregorio ^c   Arsequell, Gemma ^c   Saraiva, Maria João ^a,b   Cardoso, Isabel ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

Author keywords

Alzheimer's disease; amyloid peptide; behavior; cerebrospinal fluid; iododiflunisal; plasma; transgenic mouse; transthyretin

Indexed keywords

AMYLOID BETA PROTEIN; DIFLUNISAL; IODODIFLUNISAL; MEGLUMINE; PREALBUMIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRANSGENIC MOUSE;

ALZHEIMER'S DISEASE; AMYLOID-Β PEPTIDE; BEHAVIOR; CEREBROSPINAL FLUID; IODODIFLUNISAL; PLASMA; TRANSGENIC MOUSE; TRANSTHYRETIN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; COGNITION DISORDERS; DIFLUNISAL; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PREALBUMIN; PRESENILIN-1;

EID: 84893904524     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131355     Document Type: Article

References (54)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8, 429-431.
2. Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41, 1261-1268.
3. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eisenberg M, Saunders AM, Roses AD, GoldgaberD(1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 91, 8368-8372.
4. Seibert FB, Nelson JW (1941) Electrophoretic study of the blood protein response in tuberculosis. J Biol Chem 143, 29-38.
5. Oliveira SM, Cardoso I, Saraiva MJ (2012) Transthyretin: Roles in the nervous system beyond thyroxine and retinol transport. Expert Rev Endocrinol Metab 7, 181-189.
6. Robbins J (1991) Thyroid hormone transport proteins and the physiology of hormone binding. In Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, Braverman LE, Utiger RD, ed. J.B. Lippincott Co., New York, pp. 111-125.
7. Loun B, Hage DS (1992) Characterization of thyroxinealbumin binding using high-performance affinity chromatography. I. Interactions at the warfarin and indole sites of albumin. J Chromatogr 579, 225-235.
8. Schwarzman AL, Goldgaber D (1996) Interaction of transthyretin with amyloid beta-protein: Binding and inhibition of amyloid formation. Ciba Found Symp 199, 146-160; discussion 160-144.
9. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16, 389-397.
10. Ribeiro CA, Santana I, Oliveira C, Baldeiras I, Moreira J, Saraiva MJ, Cardoso I (2012) Transthyretin decrease in plasma of MCI and AD patients: Investigation of mechanisms for disease modulation. Curr Alzheimer Res 9, 881-889.
11. Han SH, Jung ES, Sohn JH, Hong HJ, Hong HS, Kim JW, Na DL, Kim M, Kim H, Ha HJ, Kim YH, Huh N, Jung MW, Mook-Jung I (2011) Human serum transthyretin levels correlate inversely with Alzheimer's disease. J Alzheimers Dis 25, 77-84.
12. Velayudhan L, Killick R, Hye A, Kinsey A, Guentert A, Lynham S, Ward M, Leung R, Lourdusamy A, To AW, Powell J, Lovestone S (2012) Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 28, 369-375.
13. LazarovO, Robinson J,TangYP, Hairston IS,Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701-713.
14. Oliveira SM, Ribeiro CA, Cardoso I, Saraiva MJ (2011) Gender-dependent transthyretin modulation of brain amyloidbeta levels: Evidence from a mouse model of Alzheimer's disease. J Alzheimers Dis 27, 429-439.
15. Choi SH, Leight SN, Lee VM, Li T, Wong PC, Johnson JA, Saraiva MJ, Sisodia SS (2007) Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27, 7006-7010.
16. Buxbaum JN,Ye Z, Reixach N, FriskeL,LevyC, Das P, Golde T, Masliah E, Roberts AR, Bartfai T (2008) Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 105, 2681-2686.
17. Wati H, Kawarabayashi T, Matsubara E, Kasai A, Hirasawa T, Kubota T, HarigayaY, Shoji M, Maeda S (2009) Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Brain Pathol 19, 48-57.
18. Doggui S, Brouillette J, Chabot JG, Farso M, QuirionR(2010) Possible involvement of transthyretin in hippocampal betaamyloid burden and learning behaviors in a mouse model of Alzheimer's disease (TgCRND8). Neurodegener Dis 7, 88-95.
19. Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36, 411-423.
20. Quintas A, Saraiva MJ, Brito RM (1997) The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett 418, 297-300.
21. Cardoso I, Goldsbury CS, Muller SA, Olivieri V, Wirtz S, Damas AM, Aebi U, Saraiva MJ (2002) Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol 317, 683-695.
22. Almeida MR, Saraiva MJ (2012) Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Lett 586, 2891-2896.
23. Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ (2005) Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 4, 587-596.
24. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109, 9629-9634.
25. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ (2004) Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 381, 351-356.
26. Baures PW, Oza VB, Peterson SA, Kelly JW (1999) Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7, 1339-1347.
27. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A 93, 15051-15056.
28. Morais-de-Sa E, Pereira PJ, Saraiva MJ, Damas AM (2004) The crystal structure of transthyretin in complex with diethylstilbestrol: A promising template for the design of amyloid inhibitors. J Biol Chem 279, 53483-53490.
29. Raghu P, Reddy GB, Sivakumar B (2002) Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Arch Biochem Biophys 400, 43-47.
30. Costa R, Goncalves A, Saraiva MJ, Cardoso I (2008) Transthyretin binding to Aβ peptide-impact on Aβ fibrillogenesis and toxicity. FEBS Lett 582, 936-942.
31. Schwarzman AL, Tsiper M, Wente H, Wang A, Vitek MP, Vasiliev V, Goldgaber D (2004) Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11, 1-9.
32. Ribeiro CA, Saraiva MJ, Cardoso I (2012) Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide-relevance in Alzheimer's disease. PLoS One 7, e45368.
33. Cardoso I, Almeida MR, Ferreira N, Arsequell G, Valencia G, Saraiva MJ (2007) Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochem J 408, 131-138.
34. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
35. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad SciUS A 90, 2375-2379.
36. Huang YL, Saljo A, Suneson A, Hansson HA (1995) A new approach for multiple sampling of cisternal cerebrospinal fluid in rodents with minimal trauma and inflammation. J Neurosci Methods 63, 13-22.
37. Saraiva MJ, Costa PP, Goodman DS (1988) Transthyretin (prealbumin) in familial amyloidotic polyneuropathy: Genetic and functional aspects. Adv Neurol 48, 189-200.
38. Gales L, Macedo-Ribeiro S, Arsequell G, Valencia G, Saraiva MJ, Damas AM (2005) Human transthyretin in complex with iododiflunisal: Structural features associated with a potent amyloid inhibitor. Biochem J 388, 615-621.
39. Hornstrup LS, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A (2013) Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler Thromb Vasc Biol 33, 1441-1447.
40. Du J, Cho PY, Yang DT, Murphy RM(2012) Identification of beta-amyloid-binding sites on transthyretin. Protein Eng Des Sel 25, 337-345.
41. Du J, Murphy RM (2010) Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry 49, 8276-8289.
42. Yang DT, Joshi G, Cho PY, Johnson JA, Murphy RM (2013) Transthyretin as both Sensor and Scavenger of Abeta Oligomers. Biochemistry 52, 2849-2861.
43. Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: Effects on microglial functions. Pharmaceuticals 3, 1949-1964.
44. Coté S, Carmichael P, Verreault R, Lindsay J, Lefebvre J, Laurin D (2012) Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement 8, 219-226.
45. Yagiela JA, Dowd FJ, Johnson B, Mariotti A, Neidle EA (2011) Pharmacology and Therapeutics for Dentistry, 6th edition. Mosby Elsevier, St. Louis, MO.
46. Andrew S (2008) Acute Pain. PLEASE ask the authors to provide a full reference here (Publisher, City, etc.)
47. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL (2006) Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24, 114-127.
48. Kawarabayashi T,Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381.
49. Sousa JC, Marques F, Dias-Ferreira E, Cerqueira JJ, Sousa N, Palha JA (2007) Transthyretin influences spatial reference memory. Neurobiol Learn Mem 88, 381-385.
50. Nunes AF, Saraiva MJ, Sousa MM (2006) Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J 20, 166-168.
51. Sousa JC, Grandela C, Fernandez-Ruiz J, de Miguel R, de Sousa L, Magalhaes AI, Saraiva MJ, Sousa N, Palha JA(2004) Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 88, 1052-1058.
52. Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, Feinstein DL (2007) Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28, 1206-1214.
53. Herbert J, Wilcox JN, Pham KT, Fremeau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA et al. (1986) Transthyretin:Achoroid plexus-specific transport protein in human brain. The 1986S. Weir Mitchell award. Neurology 36, 900-911.
54. Hawkins J, Harrison DC, Ahmed S, Davis RP, Chapman T, Marshall I, Smith B, Mead TL, Medhurst A, Giblin GM, Hall A, Gonzalez MI, Richardson J, Hussain I (2011) Dynamics of Abeta42 reduction in plasma, CSF and brain of rats treated with the gamma-secretase modulator, GSM-10h. Neurodegener Dis 8, 455-464.